10-Q: NovelStem Reports Q2 Profit Amid Debt Relief, Asset Sale

NovelStem International Corp. posted a significant net income in Q2 2025, driven by the settlement of a major litigation funding liability and the disposal of an equity investment, despite ongoing operational challenges and a going concern warning.

Summary

• NovelStem International Corp. reported a net income of $2,546,625 for the six months ended June 30, 2025, a substantial improvement from a net loss of $(605,905) in the prior year period.
• The positive financial results were primarily due to a $1,697,024 relief of indebtedness income and a $1,171,760 gain on disposal of an equity method investment.
• Total liabilities significantly decreased to $1,990,204 as of June 30, 2025, from $5,304,486 at December 31, 2024, largely due to the settlement of a litigation funding agreement.
• The company's investment in NetCo was sold for $1,300,000 to settle a $2,959,625 litigation funding liability with Omni Bridgeway on May 9, 2025.
• General and administrative expenses decreased by approximately $169,000 to $158,537 for the six months ended June 30, 2025, compared to $327,336 in the same period last year, mainly due to reduced legal and audit fees.
• NewStem Ltd., an Israeli biotech company in which NovelStem held a 30.51% equity interest, is in liquidation due to its inability to raise funds, leading to a full impairment of NovelStem's investment to $0.
• NovelStem has an agreement to receive up to $3,750,000 from Yissum (Hebrew University's commercial division) if NewStem's technology or licenses are re-licensed or monetized.
• Cash on hand decreased to $1,106 as of June 30, 2025, from $6,099 at December 31, 2024.
• Net cash used in operating activities improved to $(110,493) for the six months ended June 30, 2025, from $(170,192) in the prior year period.
• A promissory note with a shareholder (Stephen Gans) was amended on May 16, 2025, removing a $650,000 guarantee and replacing it with fixed interest of $36,000, extending the maturity to September 30, 2025.
• The Executive Chairman, Jan Loeb, provided an interim bridge loan of $105,500 during the first half of 2025, with an additional $18,000 advanced in July 2025.

Sentiment

Score: 2

Explanation: The company reported a net income due to significant non-recurring gains from debt relief and asset disposal, which temporarily improved the balance sheet by reducing liabilities and the accumulated deficit. However, the underlying operational cash flow remains negative, cash on hand is critically low, and a key asset (NewStem) is in liquidation. The company explicitly states substantial doubt about its ability to continue as a going concern and has identified material weaknesses in internal controls. The positive financial figures are not indicative of sustainable operational health, and the company faces severe liquidity challenges and an ongoing need for external funding.

Positives

• Achieved a net income of $2,546,625 for the six months ended June 30, 2025, a significant turnaround from a net loss in the prior year.
• Successfully settled a substantial litigation funding liability of $2,959,625 for $1,300,000 through the sale of the NetCo interest, resulting in a large relief of indebtedness income.
• Realized a gain on disposal of equity method investment of $1,171,760 from the NetCo sale.
• Reduced general and administrative expenses by approximately $169,000, indicating improved cost control.
• Reduced total liabilities by over $3.3 million from December 31, 2024, to June 30, 2025.
• Reduced the accumulated shareholders deficit by over $3.1 million from December 31, 2024, to June 30, 2025.

Negatives

• The company continues to operate with a significant accumulated deficit of approximately $294,000,000 since inception.
• NewStem Ltd., a key equity investment, is in liquidation due to its inability to raise funds, leading to a full impairment of the investment.
• Cash balance is critically low at $1,106 as of June 30, 2025, down from $6,099 at December 31, 2024.
• The company continues to use cash in operating activities, with a net cash outflow of $110,493 for the six months ended June 30, 2025.
• The net income is largely driven by non-recurring events (debt relief, asset disposal) rather than sustainable operational profitability.
• Administrative fee income, a previous revenue source, has ceased ($0 for the six months ended June 30, 2025).

Risks

• Substantial doubt about the company's ability to continue as a going concern due to accumulated deficit and ongoing need for additional funds.
• Dependence on obtaining additional financing and fundraising to continue operations.
• Uncertainty regarding the monetization of NewStem's intangible assets and technology, with no assurance of realizing value from the $3,750,000 agreement with Yissum.
• Material weaknesses identified in internal control over financial reporting, specifically insufficient resources for proper segregation of duties, which could lead to material misstatements.
• The arbitrator in the NetCo legal proceeding did not award damages or cede operating control, making it difficult to maximize the asset's potential (though the asset was subsequently sold, the underlying issue of control and value realization was a risk).

Future Outlook

The company's ability to continue as a going concern is dependent on securing additional financing and fundraising, as well as successfully monetizing the intangible assets and technology of NewStem. Management acknowledges there is no assurance of success in these efforts or that NewStem's technology will become profitable.

Management Comments

• "Our continuation as a going concern is dependent upon our ability to work with Yissum to monetize the former NewStem license agreement and intangible assets and the continuing financial support from our shareholders as well as obtaining additional outside funding."
• "Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from financing on terms acceptable to the Company, or that NewStems technology will be monetized and become profitable."
• "We have identified material weaknesses in our internal control and procedures and internal control over financial reporting."

Industry Context

NovelStem operates as a holding company with historical interests in biotech (NewStem) and media (NetCo). The liquidation of NewStem and the sale of NetCo indicate a significant shift away from direct operational involvement in these sectors. The company's future hinges on the monetization of intellectual property, a common strategy for distressed or asset-heavy entities in the biotech and media IP space, but success is highly uncertain given NewStem's liquidation status and the challenges in monetizing intellectual property without active development.

Comparison to Industry Standards

• The company's accumulated deficit of approximately $294 million and current cash balance of $1,106 are significantly below industry standards for a publicly traded company, particularly in the biotech or media sectors, which typically require substantial capital for R&D or content development.
• The reliance on related-party financing and bridge loans from the Executive Chairman is indicative of a company struggling to secure traditional institutional funding, unlike more established biotech firms or media companies that access broader capital markets.
• The full impairment of the NewStem investment and its liquidation status contrast sharply with successful biotech companies that typically advance assets through clinical trials and commercialization, highlighting a failure in the company's previous investment strategy.
• The settlement of a $2.96 million liability for $1.3 million is a positive, but such large debt restructurings are often a sign of severe financial distress, unlike financially stable companies that manage liabilities through regular operations or standard refinancing.

Corporate Governance

Legal Proceedings

• The company was the claimant in an arbitration proceeding against its 50% partner in NetCo, asserting claims for breach of joint venture agreement and fiduciary duty related to the exploitation of Net Force intellectual property.
• The arbitrator ruled in NovelStem's favor on contract interpretation and the partner's failure to use good faith efforts to license and exploit Net Force, confirming NovelStem's right to use 'Tom Clancy's' name in the title.
• However, the arbitrator did not award any damages to the company and did not cede operating control of the joint venture.
• Costs related to the litigation funding agreement with Omni Bridgeway, totaling approximately $2,900,000, were recognized as a liability.
• This liability, including accrued interest, was fully settled on May 9, 2025, for $1,300,000 through the sale of the NetCo interest to the JV partner.

Related Party Transactions

• Bridge loan from Jan Loeb (Executive Chairman) totaling $105,500 during the six months ended June 30, 2025, with an additional $18,000 in July 2025, accruing 10% interest.
• Note agreements with Jan Loeb (Executive Chairman) and Jerry Wolasky (shareholder and Board member) for total borrowings of $750,000, bearing 10% interest per annum and maturing December 31, 2025.
• Long-term note payable with a shareholder (Stephen Gans) for $300,000, amended on May 16, 2025, to remove a $650,000 guarantee and replace it with fixed interest of $36,000, extending maturity to September 30, 2025.

Stakeholder Impact

• **Shareholders**: The significant net income from debt relief and asset sale temporarily improved the balance sheet and reduced the accumulated deficit, but the underlying operational challenges and going concern doubt pose substantial risks to long-term shareholder value. Dilution is a potential risk if future capital raises involve equity issuance.
• **Creditors**: The settlement of the large litigation funding liability is positive for creditors, as a significant debt was resolved. However, the company's low cash balance and ongoing need for funding indicate potential future repayment risks for other creditors.
• **Employees**: The company's precarious financial position and going concern warning suggest potential instability, which could impact employee morale and job security, though the filing does not detail employee-specific impacts.
• **Customers/Suppliers**: As a holding company with impaired and liquidated assets, direct impact on customers and suppliers is minimal, but the overall financial instability could affect any remaining operational relationships.

Next Steps

• Obtain additional funds through financing and fundraising to continue operations.
• Work with Yissum to monetize the former NewStem license agreement and intangible assets, with a potential to receive up to $3,750,000.
• Address and remediate identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

Despite a reported net income, the company's financial health is extremely fragile. The profit is entirely non-recurring, stemming from debt forgiveness and asset disposal, not sustainable operations. Cash on hand is critically low, and the company explicitly warns of substantial doubt about its ability to continue as a going concern. A key asset (NewStem) is in liquidation, and there are identified material weaknesses in internal controls. The company remains heavily reliant on related-party financing and future capital raises, which are uncertain. For a seasoned investor, these factors indicate severe fundamental weaknesses and high risk, making the stock a strong sell.

Keywords

Biotech, SEC filing, 10-Q, Financial results, Debt restructuring, Equity investment, Going concern, Liquidation, Convertible debt, Related party transactions, Corporate governance, Risk factors